HR Execs on the Move

Octapharma USA

www.octapharma.com

 
Octapharma is committed to promoting excellence in patient care and providing valuable information to the medical and patient community. This will help to better manage the treatment of disease and to improve patient safety and population health
  • Number of Employees: 25-100
  • Annual Revenue: $100-250 Million

Executives

Name Title Contact Details
Lynn Maloney
Vice President, Human Resources Profile
Sylvia Werner
Senior Director, Clinical R&D Hematology Profile

Similar Companies

Zuni Technologies Inc

Zuni Technologies Inc is a Zuni, NM-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Tri-Source Pharma

Tri-Source Pharma is a pharmaceutical manufacturer/distributor operating in both the human and animal health care industries.

Portage Biotech

Portage is a unique entity in the world of biotechnology, catalyzing R&D to produce more quality clinical programs and maximize potential returns.

Primera Biosystems Inc d/b/a PrimeraDx

Primera Biosystems Inc d/b/a PrimeraDx is a Mansfield, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Adagio Therapeutics

Adagio Therapeutics, Inc` is a clinical-stage a biotechnology company developing best-in-class antibodies that can broadly neutralize SARS-CoV-2, SARS-CoV-1 and additional pre-emergent coronaviruses` Our candidates are optimized using Adimab’s industry-leading antibody engineering capabilities and are designed to provide patients and clinicians with an unsurpassed combination of potency, breadth, durable protection (via half-life extension), manufacturability, tolerability, and affordability` Our portfolio of SARS-CoV-2 antibodies includes multiple, non-competing antibodies with distinct binding epitopes` Pre-clinical data show that our lead antibody ADG20 matches or exceeds the potency and coverage of other clinical SARS-CoV-2 antibody programs` We plan to advance ADG20 aggressively through global clinical trials for both the prevention and treatment of symptomatic COVID-19 and anticipate data from both prevention and treatment clinical trials in 2021` Adagio has secured manufacturing capacity for the production of ADG20 with third party contract manufacturers through the completion of clinical trials and, if approved by regulatory authorities, through initial commercial launch`